Choose a language
Holistic approach for characterization and control
Drug stored in glass primary containers risk losing efficacy and safety when not properly tested for corrosion or delamination. These phenomena occur when a drug interacts with the inner glass surface over time, causing glass matrix dissolution. In 2011, the FDA issued an industry warning leading to aggressive and extensive testing. We at Stevanato Group leverage our expertise as a leading glass container manufacturer and as an independent laboratory investigating delamination to present:
Recommended attendees include those who are:
Lab Advanced Technology Analyst, Stevanato Group US Technical Excellence Center (TEC)
Alan Xu is leading key initiatives at Stevanato Group’s new US TEC in Boston, MA, by leveraging his background in developing pharmaceutical combination devices. Alan was previously an Engineering Manager leading the development, design transfer, and production verification of a novel primary container in a medical device start-up partnering with large pharmaceutical companies. Alan’s specialty is in medical device development and characterization, CMO management, and root cause investigations. Alan holds a degree in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).
SG Lab Analytics Researcher
Serena Panighello is a researcher at SG Lab Analytics. Her role is mainly related to studying glass corrosion mechanisms and container-drug interaction consultancy. She holds a Ph.D. in Chemical Sciences from Ca' Foscari University-Venice featuring a joint research program with the National Institute of Chemistry-Slovenia. During the Ph.D., she was awarded a Paul Award at the New Researchers Forum during the SGT (Society of Glass Technology) annual conference in the UK.